AOD-9604 vs GH-Based Approaches
AOD-9604 is a fragment of human growth hormone (amino acids 176–191) studied specifically because it appears to separate lipolytic activity from growth-hormone receptor signalling. Research indicates it does not bind the GH receptor or stimulate IGF-1 production — unlike GHRH analogs such as Tesamorelin, which work precisely by raising GH and IGF-1.
| Property | AOD-9604 | Tesamorelin |
|---|---|---|
| What it is | C-terminal fragment of hGH (aa 176–191), tyrosine-modified | GHRH analog — stimulates endogenous GH release |
| GH receptor binding | Does not bind the GH receptor in the studied literature | Not applicable — acts upstream at the GHRH receptor |
| IGF-1 effect | Does not stimulate IGF-1 production | Raises IGF-1 as the intended downstream marker |
| Studied mechanism | Beta-adrenergic receptor interaction in adipose tissue; lipolysis | GH/IGF-1 axis activation increasing lipolysis in visceral depots |
| Notable regulatory note | Received GRAS status from the FDA for certain food applications | Extensive randomised controlled trial record in a clinical population |
Separating lipolysis from GH signalling
The research interest in AOD-9604 rests on a specific claim in the literature: that the fragment retains the fat-mobilising activity associated with growth hormone while not producing the anabolic, hyperglycemic, or epiphyseal effects that follow from GH-receptor activation. Animal studies from the early 2000s reported dose-dependent lipolytic activity and inhibition of lipogenesis in adipocytes without the IGF-1 rise. GHRH analogs take the opposite approach — the GH and IGF-1 elevation is the mechanism, not a side effect.
How the evidence differs
The two are at very different points on the evidence curve. Tesamorelin carries randomised controlled trials with visceral fat as a measured endpoint. AOD-9604's record is predominantly preclinical, with later human trials in obesity not replicating the early animal findings — a limitation worth stating plainly rather than omitting. Both are supplied strictly for laboratory research use.
Related questions
How does AOD-9604 differ from full-length growth hormone in its metabolic effects?
AOD-9604 is a synthetic analog of the C-terminal fragment (residues 177–191) of human growth hormone, modified with a tyrosine at the N-terminus. Unlike full-length hGH, AOD-9604 does not bind the growth hormone receptor or stimulate IGF-1 production, meaning it does not produce the anabolic, hyperglycemic, or epiphyseal effects of exogenous GH. Research has focused on its interaction with beta-adrenergic receptors in adipose tissue as a potential mechanism for selective lipolysis. Animal studies have demonstrated fat-mobilizing activity without the metabolic side effects associated with intact GH.
What is the proposed mechanism by which Tesamorelin reduces visceral adipose tissue?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized by the addition of a trans-3-hexenoic acid group at the N-terminus, which confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation. It stimulates the pituitary to release endogenous growth hormone in a pulsatile, physiological pattern, which in turn elevates IGF-1. The resulting GH/IGF-1 axis activation increases lipolysis preferentially in visceral fat depots — a mechanism demonstrated in randomized controlled trials of HIV-associated lipodystrophy, where significant reductions in trunk fat were observed at 26–52 weeks.
What distinguishes a GHRH analog from exogenous HGH in terms of GH release?
Exogenous recombinant human growth hormone (rhGH) delivers a sustained, non-pulsatile elevation of circulating GH that bypasses normal hypothalamic-pituitary regulation. In contrast, GHRH analogs stimulate the pituitary to secrete its own GH in response to the hypothalamic signal, preserving pulsatility (high nocturnal pulses, lower daytime levels) and maintaining negative feedback through somatostatin. This physiological pattern is thought to reduce risks associated with continuous GH excess, including insulin resistance and IGF-1 overshoot. The relative benefit of GHRH-stimulated GH versus exogenous GH is an active area of endocrinological research.
Mechanisms described from published literature, predominantly preclinical. Not a recommendation and not a description of human use. For laboratory research use only.